Neuraminidase is a crucial Glycosyl Functional Enzyme found on the surface of influenza viruses, playing a pivotal role in viral replication and spread. By cleaving sialic acid residues from host cell receptors and newly formed virions, this Glycocalyx-Degrading Enzyme facilitates the release of progeny viruses, preventing their aggregation and enabling efficient transmission to neighboring cells. This enzymatic activity is essential for the viral life cycle, making neuraminidase a key target for antiviral drugs. Structurally, neuraminidase belongs to the viral neuraminidase family, with subtypes varying among influenza strains.

Fig. 1. Influenza replication cycle & neuraminidase inhibitor action. (OA Literature) Fig.1 Influenza virus replication pathway and the effect of neuraminidase inhibitors.¹

Service Overview

Are you currently facing high antigenic drift in seasonal vaccine targets, metastatic escape in oncology models, or the structural complexity of selective sialidase inhibition? Creative Biolabs provides an end-to-end technical solution for the design, expression, and characterization of sialidases across viral, bacterial, and human isoforms. Our neuraminidase development service helps you accelerate drug discovery and achieve broad-spectrum immunogenicity through proprietary epitope-masking techniques and high-resolution glycan profiling.

Neuraminidase Development Workflow

Phase I

Epitope Mapping & In Silico Design

We employ cutting-edge structural modeling techniques to precisely identify conserved, functional domains on the neuraminidase enzyme. By analyzing its 3D architecture, we pinpoint critical regions essential for enzymatic activity and antigenicity, enabling rational design of inhibitors or vaccine candidates. This computational approach accelerates discovery by focusing on targets with high therapeutic potential.

Phase II

Expression & Purification

Leveraging optimized mammalian or insect cell expression systems, we achieve milligram-scale production of neuraminidase proteins with exceptional purity. Our streamlined purification protocols ensure structural integrity and functional activity, providing high-quality antigens or enzymes for downstream assays. This scalable workflow supports both preclinical studies and industrial-scale applications.

Phase III

High-Throughput Bio-Assay

We conduct comprehensive kinetic profiling and cross-reactivity analyses using proprietary enzymatic inhibition assays. These high-throughput platforms enable rapid screening of compound libraries, quantifying potency, selectivity, and mechanism of action. By generating detailed dose-response curves, we identify leads with optimal inhibitory profiles for further development.

Phase IV

Structural Validation

X-ray crystallography is employed to resolve the atomic-level binding interactions between leads and neuraminidase. These data confirm the predicted binding mode, reveal key residues, and guide structure-based optimization. Structural insights ensure leads are rationally refined for enhanced efficacy and reduced off-target effects.

Phase V

Lead Optimization

Guided by biophysical and structural data, we iteratively refine lead compounds to improve pharmacokinetic (ADME/PK) properties. Medicinal chemistry strategies enhance solubility, metabolic stability, and bioavailability while maintaining potency. This iterative process yields preclinical candidates with balanced profiles for advanced testing and clinical development.

Fig. 2. Neuraminidase development workflow. (Creative Biolabs AI) Fig.2 Illustrative diagram of neuraminidase development.

Applications

Antiviral Drug Discovery & Optimization

Our neuraminidase development service accelerates the identification of novel inhibitors by providing high-purity enzymes and high-throughput assays. This enables rapid screening of compound libraries, structure-activity relationship (SAR) studies, and optimization of leads with improved potency and selectivity against influenza strains.

Vaccine Antigen Design

We support vaccine development by mapping conserved epitopes on neuraminidase, ensuring broad-spectrum immunity. Structural insights guide the design of stabilized antigens, enhancing immunogenicity and reducing viral escape mutations for next-generation influenza vaccines.

Resistance Mechanism Studies

Our service aids in characterizing drug-resistant neuraminidase variants through enzymatic assays and structural analysis. By identifying mutations that confer resistance, researchers can design inhibitors that overcome these mechanisms, prolonging the efficacy of existing antivirals.

Diagnostic Assay Development

We provide recombinant neuraminidase proteins for the development of sensitive diagnostic tools, such as ELISA or lateral flow assays. These assays enable rapid detection of viral neuraminidase activity, facilitating early diagnosis and surveillance of influenza outbreaks.

Enzyme Engineering for Biotechnology

Our expertise extends to engineering neuraminidase variants with enhanced stability or altered substrate specificity for biotechnological applications. These modified enzymes are valuable for glycoscience research, bioconjugation, and the synthesis of sialic acid-containing therapeutics.

See How We Can Aid Your Endeavors

Key Features

Advanced Structural Epitope Mapping
Our service employs cutting-edge computational modeling and cryo-EM to identify conserved, functional epitopes on neuraminidase, enabling rational design of high-affinity inhibitors or vaccines.

High-Yield Mammalian Expression Systems
We utilize optimized mammalian or insect cell lines for scalable, milligram-scale production of neuraminidase proteins with native folding and enzymatic activity, ensuring reliability for downstream applications.

High-Throughput Enzymatic Inhibition Assays
Our proprietary bioassays rapidly screen compound libraries, providing kinetic data on IC50 values, selectivity, and mechanism of action to prioritize leads with optimal therapeutic potential.

ADME/PK-Driven Lead Optimization
Our team refines lead compounds through iterative medicinal chemistry, enhancing solubility, metabolic stability, and bioavailability while maintaining neuraminidase inhibitory potency.

Customer Reviews

Enhanced Characterization
"Using the neuraminidase development service in our research has significantly improved our ability to characterize drift-resistant epitopes that were previously masked by HA immunodominance."- 10 months ago, Dr. A***n L.

Increased Yields
"Using the neuraminidase development service in our research has significantly improved the yields of traditionally recalcitrant bacterial sialidases, allowing us to move into high-throughput biofilm disruption studies."- 1 year ago, Prof. R***t K.

FAQs

Q: How do you ensure selectivity between viral and human neuraminidase isoforms?

A: We utilize structure-guided design to target unique residues in the active site and secondary sialic-acid binding sites that differ significantly between viral and mammalian isoforms.

Q: Can Creative Biolabs handle neuraminidase development for emerging pandemic strains?

A: Yes, our platform is designed for rapid response. We can initiate antigen design within 72 hours of receiving a target sequence, facilitating accelerated pandemic preparedness.

Q: Do you offer support for glycan-shield engineering in oncology?

A: Absolutely. We specialize in identifying human sialidase inhibitors that can be used to re-sensitize "glycan-shielded" tumors to standard-of-care immunotherapy.

Q: What expression systems are available for recombinant NA production?

A: We offer a range of mammalian and insect systems, ensuring that post-translational modifications, specifically glycosylation, are biologically relevant.

Q: How does your service compare to traditional small-molecule screening?

A: Unlike generic screening, our service is "target-aware." We integrate structural biology from the outset, ensuring that leads are designed for potency, selectivity, and clinical durability.

Extended Services

Glycan Modification and Labeling Services

Our service specializes in precise chemical or enzymatic modification of glycans to introduce functional groups or fluorescent labels, enabling detailed structural and functional studies of glycoproteins. Ideal for glycosylation profiling, biomarker discovery, and therapeutic conjugate development.

Glycoprotein Structure Analysis Services

We provide comprehensive structural characterization of glycoproteins using advanced techniques like mass spectrometry, NMR, and X-ray crystallography to map glycosylation sites and define glycan-protein interactions. Perfect for quality control, mechanism-of-action studies, and rational drug design.

Creative Biolabs provides a world-class neuraminidase development service that integrates structural biology, high-throughput characterization, and lead optimization. For detailed technical specifications or to discuss a collaborative project, please reach out to our specialist team.

Reference

Laborda, Pedro, Su-Yan Wang, and Josef Voglmeir. "Influenza neuraminidase inhibitors: synthetic approaches, derivatives and biological activity." Molecules 21.11 (2016): 1513. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/molecules21111513.

For Research Use Only.

Related Services

Online Inquiry